Work

Corrigendum to: Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment [Surgery. 2020 Jan;167(1):189-196. doi: 10.1016/j.surg.2019.05.092. Epub 2019 Oct 16.PMID: 31629542]

Year: 2021

Type: erratum

Source: Surgery

DOI: 10.1016/j.surg.2021.03.028

Authors: R. Guenter, T. Aweda, D.M. Carmona Matos, S. Jang, J. Whitt, Y.Q. Cheng, X.M. Liu, H. Chen, S.E. Lapi, R. Jaskula-Sztul

Institutions: University of Alabama at Birmingham, UAB Medicine, San Juan Bautista School of Medicine, University of North Texas Health Science Center

Language: English

Topic: Neuroendocrine Tumor Research Advances

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Biomedical Imaging and Bioengineering, National Center for Advancing Translational Sciences

Awards: UAB Center for Clinical and Translational Sciences (CCTS), Center for Clinical and Translational Science, Development and Functional Assessment of Cardiovascular Tissue Engineering Therapy (CVTE) T32 Training Grant, Somatostatin receptor 2 (SSTR2) antibody-drug conjugate for pancreatic neuroendocrine tumor (PanNET) therapy, UAB Center for Clinical and Translational Science (CCTS), Comprehensive Cancer Center Support Grant, UAB Diabetes Research Center

OpenAlex ID: W3156196817

Cites:

Cited by:

Related to: 10